Drug Trial Radar · NCT06169527
A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
303
Actual
Start
Nov 28, 2023
Primary completion
Jul 5, 2028
Study completion Jul 5, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Dec 13, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a long-term study to collect data over 3 years in order to find out what is likely to happen in the future regarding participants 6 years of age and older who receive dupilumab for Atopic Dermatitis (AD) commonly known as Eczema, and to characterize real-world effectiveness, safety and use patterns of dupilumab in real world setting in France. Patients will be invited to participate if initiating treatment with dupilumab for AD according to French-specific prescribing information. The decision of initiation of the treatment is independent to the study's participation. The study will be conducted in approximately 50 centers in France to evaluate a representative sample of patients treated in France. At each participating site, all AD participants who receive an initial prescription for dupilumab will be invited to participate in this study, until the enrollment goal is achieved.
Conditions
- Atopic Dermatitis
Interventions
DupilumabDrug
Dupilumab cohort
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demographic characteristics of participants who receive dupilumab for ADTime frame: At baseline
- Weight characteristics of participants who receive dupilumab for ADTime frame: At baseline
- Height characteristics of participants who receive dupilumab for ADTime frame: At baseline
- Medical history characteristics of participants who receive dupilumab for ADTime frame: At baseline
- Comorbidities and treatments change from baselineTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
- Atopic comorbidities and treatments change from baselineTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
- Change from baseline in lifestyle habits of participants who receive dupilumab for ADTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36 if applicable
- Change from baseline in dupilumab doseTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
- Change from baseline in dupilumab administrationTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
- Change from baseline in dupilumab compliance with treatmentTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
- Change from baseline in dupilumab temporary or permanent discontinuationTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
- Change from baseline in dupilumab treatment switch to another therapyTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
- Change from baseline in dupilumab treatment for concomitant AD treatmentsTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
- Change in patient's treatment satisfaction score using the Patient Global Assessment of Treatment Effect (PGATE)Time frame: At month 6, month 12, month 18, month 24, month 30, month 36
- Change in eczema severity using the Eczema Area and Severity Index (EASI)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
- Change in AD disease control using the Atopic Dermatitis Control Tool (ADCT)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
- Change in itch assessmentTime frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
- Change in sleep disturbance NRSTime frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
- Change in global patient's disease evaluation using the Patient Global Assessment of Disease Severity (PGADS)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
- Change in global patient's disease evaluation using the Caregiver Global Assessment of Disease (CGAD)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
- Change in Dermatology Life Quality Index (DLQI)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
- Change in Dermatitis Family Impact Questionnaire (DFI)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
- Change in European Quality of Life-5 Dimensions-3 level score (EQ-5D-3L)Time frame: At baseline, month 6, month 12, month 18, month 24, month 30, month 36
- Change in Work Productivity and Activity Impairment Questionnaire, Atopic Dermatitis (WPAI-AD)Time frame: At month 6, month 12, month 18, month 24, month 30, month 36
- Number of Adverse Events (AE)Time frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
- Change from baseline in Drug SurvivalTime frame: At baseline, month 3, month 6, month 12, month 18, month 24, month 30, month 36
Locations
42 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number: 2500041
Amiens, France
Investigational Site Number: 2500037
Angers, France
Investigational Site Number: 2500021
Argenteuil, France
Investigational Site Number: 2500044
Armentières, France
Investigational Site Number: 2500018
Arras, France
Investigational Site Number: 2500011
Ars-Laquenexy, France
Investigational Site Number: 2500023
Avignon, France
Investigational Site Number: 2500001
Besançon, France
Investigational Site Number: 2500003
Bron, France
Investigational Site Number: 2500043
Caen, France
Investigational Site Number: 2500050
Chambéry, France
Investigational Site Number: 2500006
Clermont-Ferrand, France
Investigational Site Number: 2500005
Dijon, France
Investigational Site Number: 2500004
Epagny Metz Tessy, France
Investigational Site Number: 2500039
Fort-de-France, France
Investigational Site Number: 2500045
La Tronche, France
Investigational Site Number: 2500019
Le Havre, France
Investigational Site Number: 2500040
Le Mans, France
Investigational Site Number: 2500038
Les Sables-d'Olonne, France
Investigational Site Number: 2500048
Levallois-Perret, France
Investigational Site Number: 2500032
Lille, France
Investigational Site Number: 2500002
Limoges, France
Investigational Site Number: 2500036
Lorient, France
Investigational Site Number: 2500029
Marseille, France
Investigational Site Number: 2500028
Montpellier, France
Investigational Site Number: 2500024
Nantes, France
Investigational Site Number: 2500025
Nice, France
Investigational Site Number: 2500020
Nice, France
Investigational Site Number: 2500016
Pau, France
Investigational Site Number: 2500009
Périgueux, France
Investigational Site Number: 2500042
Poitiers, France
Investigational Site Number: 2500022
Pontoise, France
Investigational Site Number: 2500014
Romans-sur-Isère, France
Investigational Site Number: 2500008
Rouen, France
Investigational Site Number: 2500015
Saint-Germain-en-Laye, France
Investigational Site Number: 2500027
Saint-Mandé, France
Investigational Site Number: 2500026
Saint-Nazaire, France
Investigational Site Number: 2500035
Saint-Pierre, France
Investigational Site Number: 2500013
Saint-Pierre, France
Investigational Site Number: 2500012
Toulouse, France
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.